AzTrials
AzTrials

Glaucoma, Open-AngleFPSPLTTCOAGNCT02679482

Following Patients After Selective and Pascal Laser Trabeculoplasty for Treatment of Chronic Open-Angle Glaucoma

An observational study of Glaucoma, Open-Angle and Glaucoma, Primary Open Angle, run by Fundación Oftalmológica Nacional at 1 site in Colombia.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The purpose of this study is to follow and describe the outcomes of patients after selective and pascal laser trabeculoplasty treatment for chronic open-angle glaucoma. Read more about this study

Who is it for?
Ages 40 years and older
How many people
36 participants
Where
1 siteColombia
Study dates
Sep 2014to Oct 2016
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients diagnosed with Open-Angle Glaucoma with a non-optimal intraocular pressure control with topical/oral medications, who underwent to laser trabeculoplasty treatment, attending the Fundacion Oftalmológica Nacional between June 2014 and july 2016 on Bogotá-Colombia.

Who may be able to join

  • Subjects of either sex, aged ≥ 40 years
  • Best distant visual acuity, better than or equal to 20/200
  • Diagnosis of primary open-angle glaucoma, pseudoexfoliation glaucoma or pigmentary glaucoma, with open angles by Posner lens gonioscopy
  • Intraocular pressure ≥ 20 mmHg, with medical treatment, as monotherapy or combination therapy.
  • Previous computerized visual field within the six months previous performing trabeculoplasty
  • Patients who understand and sign the informed consent
  • Patient diagnosed with open-angle glaucoma who will undergo selective laser trabeculoplasty (SLT) with an amplitud of 360 degrees, or laser trabeculaplastia in pattern (PASCAL-Pattern Scan Laser) with an amplitud of 360 degrees. Made at initial session or in two 7 days separate sessions (each with session with an amplitude of180 degrees)

Who cannot join

  • Advanced loss on visual field within 10 degrees of central fixation in a previous 3 months visual field
  • Previous history of surgery for glaucoma management, except peripheral iridotomy
  • Corneal disease that does not allow the use of applanation tonometer nor an accurate measurement of intraocular pressure
  • Corneal disease which prevents adequate visualization of trabeculo by gonioscopy lens
  • Use of topical or systemic steroids
  • Concomitant participation in another study
  • Coexistence of other ocular pathology different than cataract.

Trial locations and contacts

1 site in 1 country.

Colombia1 site, 1 recruiting
  • Fundacion Oftalmológica Nacional

    Bogotá, Bogota D.C., 110231

    Sandra Belalcazar, MD

    Hector D Forero, MD

    Recruiting

Other trials in Colombia

About this study

The purpose of this study is to follow and describe the outcomes of patients after selective and pascal laser trabeculoplasty treatment for chronic open-angle glaucoma.

Read the detailed description

Selective laser trabeculoplasty (SLT) and pattern laser trabeculoplasty (PLT, a novel computer-guided laser that is being using to treat open-angle glaucoma) are two laser surgery methods to make a trabeculoplasty on patients with open angle glaucoma. An observational prospective study will be performed, a consecutive convenience sample patients with indication for SLT or PLT will be recruited during June 2014 to uly 2016 and follow-up until 6 months, at the Fundación Oftalmológica Nacional (Bogotá-Colombia). A non-probabilistic convenience sampling is performed, considering that the average number of patients diagnosed with chronic open-angle glaucoma undergoing to Laser trabeculoplasty at the Oftalmológica Nacional Fundacion corresponds to approximate 2 per month. Therefore it is expected to enroll one patient per month for each of the laser used (SLT and PLT) for trabeculoplasty. Finally obtaining a sample size of 18 patients per type of laser for a total of 36 patients in the recruitment period, between September 2014 and July 2016.

This study is strictly observational, that's why the laser procedure is covered by the national health insurance of each patient, as well the complications due to the same procedure. An evaluation pre trabeculoplasty and a consecutive 5 visits will be perform as follows:

Visit 0 - Pre-procedure visit: the subjects that will undergo laser trabeculoplasty either Selective laser or PASCAL laser will be invited to participate and an informed consent will be carried out. The information concerting to demographics characteristics (study eye, age, gender and ethnicity), clinical characteristics (date of glaucoma diagnosis, number of medications used to treat glaucoma, time of use of actually anti-glaucomatous topical medication) and slit lamp and ophthalmoscopy examination (corneal aspect, iris color, pupil gonioscopy, intraocular pressure, lens status, vitreous cells, vertical C/D ratio, optic nerve edge, rim characteristic [ISNT pattern], peripapilar atrophy, state of fovea, state of peripheral retina and state of choroid for both eyes) will be extracted and recorded on respective case report form (CRF). The data will be scored according to the grading criteria outlined below:

Study eye: the eye under the follow-up 0 - Right eye 1 - Left eye

Geder: the state of being male or female 0 - Male 1 - Female

Ethnicity: the fact or state of belonging to a social group that has a common national or cultural tradition.

0 - Hispanic

  1. - Black
  2. - White
  3. - Asian

Number of medications used: anti-glaucoma medication used by the patient 0 - 0

  1. - 1
  2. - 2
  3. - 3
  4. - 4

Corneal aspect: state in which the cornea is at baseline 0 - Normal 1 - Anormal

Iris color: iris pigmentation 0 - Light

  1. - Medium
  2. - Dark

Gonioscopy (Shaffer classification): amplitude of irido-corneal angle maseure by poster lens and noted by the Shaffer scale on each quadrant superior, nasal, temporal and inferor angle 0 - 0

  1. - 1
  2. - 2
  3. - 3
  4. - 4

Intraocular pressure: pressure inside the eye measured in millimeters of mercury Value in mmhg, measure with Goldman tonometer

Lens status: clouding of the lens Nuclear, Subcapsular and Cortical 0 - 0

  1. - 1
  2. - 2
  3. - 3
  4. - 4

Vitreous cells: number of cells per milimeter in the vitreous cavity 0 - 0 1 - traces 2 - +1 3 - +2 4 - +3 5 - +4

Vertical C/D ratio: relation between cup and optic nerve disc 0 - 0.1

  1. - 0.2
  2. - 0.3
  3. - 0.4
  4. - 0.5
  5. - 0.6
  6. - 0.7
  7. - 0.8
  8. - 0.9
  9. - 1.0

Optic nerve edge: regularly over the optic disc 0 - Regular

1 - Irregular

Rim characteristic [ISNT pattern]: reduction pattern in the thickness of neural ring 0 - Conserved 1 - Not conserved

Peripapilar atrophy: presence of atrophy over the disc 0 - Alfa

1 - Beta 3 - Not apply

State of fovea: normality of the fovea 0 - normal

1 - abnormal

State of peripheral retina: state of the peripheral retina 0 - normal

1 - abnormal

State of choroid: choroidal health 0 - normal

1 - abnormal

After the visit 0, a 5 consecutive visits will be performed: for 1 day, 1 week, 1 month, 3 months and 6 months after the procedure. Identical data will be extracted, ophthalmological examination data, slit lamp exam, and the computerized visual fields (CVF) (CVF only at 3 and 6 months).

One member of the investigation team will collect all information during the follow-up time, and a second one member will review and collate data.

Statistical analysis will be performed in SPSS version 21. Univariate analyzes will perform; for categorical variables, frequency distribution will be made and reported in percentage, for the quantitative variables a measure of central tendency and dispersion will be made (mean, standard deviation and range) will calculate according to the relevance for each variable analyzed. Demographics such as age and gender variables will be described. For bivariate analysis comparing polytomous qualitative and quantitative variables (evolution of intraocular pressure with the type of trabeculoplasty used, number of antihypertensive medications required after the procedure with the type of trabeculoplasty, quantification of cellularity in the anterior chamber with type of trabeculoplasty) using parametric statistical analysis with ANOVA for independent samples and nonparametric with Kruskal-Wallis test. Also comparison of quantitative variables with quantitative variables (intraocular pressure before treatment and evolution of intraocular pressure after treatment) will be performed using the parametric inferential statistical Pearson correlation analysis and for nonparametric a Spearman correlation will be made. Finally, compare qualitative variables with qualitative variables (presence of peak intraocular pressure with type of laser trabeculoplasty performed) using the non-parametric statistical analysis Chi square test, Fisher exact test and Mac Nemar will make.

Keywords
Primary Open Angle Glaucoma, Selective Laser Trabeculoplasty, Pattern Scan Laser Trabeculoplasty
Medical subject headings
Glaucoma, Open-Angle, Exfoliation Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT02679482
Study groupRoleWhat they receive
Selective laser trabeculoplasty (SLT)Patients who underwent to Selective laser trabeculoplasty
Pattern laser trabeculoplasty (PLT)Patients who underwent to Pattern laser trabeculoplasty

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Intraocular pressure

    The eye pressure measured in millimeters of mercury, measure with Goldman tonometer at follow-up period

    Measured: Six months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Feb 2016 (estimated)
  2. Study startSep 2014
  3. Primary completionSep 2016 (estimated)
  4. Study completionOct 2016 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
36 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02679482
Sponsor's protocol ID
FONCI6001
Acronym
FPSPLTTCOAG
Status last verified
Feb 2016
First submitted
6 Feb 2016
Last updated
17 Feb 2016
Results posted
No
Data monitoring committee
Yes
Individual data sharing
Undecided

Publications

  • Wang W, He M, Zhou M, Zhang X. Selective laser trabeculoplasty versus argon laser trabeculoplasty in patients with open-angle glaucoma: a systematic review and meta-analysis. PLoS One. 2013 Dec 19;8(12):e84270. doi: 10.1371/journal.pone.0084270. eCollection 2013.

    PubMed 24367649
  • Wise JB, Witter SL. Argon laser therapy for open-angle glaucoma. A pilot study. Arch Ophthalmol. 1979 Feb;97(2):319-22. doi: 10.1001/archopht.1979.01020010165017. No abstract available.

    PubMed 575877
  • Barkana Y, Belkin M. Selective laser trabeculoplasty. Surv Ophthalmol. 2007 Nov-Dec;52(6):634-54. doi: 10.1016/j.survophthal.2007.08.014.

    PubMed 18029271
  • Latina MA, Park C. Selective targeting of trabecular meshwork cells: in vitro studies of pulsed and CW laser interactions. Exp Eye Res. 1995 Apr;60(4):359-71. doi: 10.1016/s0014-4835(05)80093-4.

    PubMed 7789416
  • Sanghvi C, McLauchlan R, Delgado C, Young L, Charles SJ, Marcellino G, Stanga PE. Initial experience with the Pascal photocoagulator: a pilot study of 75 procedures. Br J Ophthalmol. 2008 Aug;92(8):1061-4. doi: 10.1136/bjo.2008.139568. Epub 2008 Jun 27.

    PubMed 18586905
  • Sambhara D, Aref AA. Glaucoma management: relative value and place in therapy of available drug treatments. Ther Adv Chronic Dis. 2014 Jan;5(1):30-43. doi: 10.1177/2040622313511286.

    PubMed 24381726
  • Buys YM. Economics of selective laser trabeculoplasty as primary therapy for glaucoma. Can J Ophthalmol. 2006 Aug;41(4):419-20. doi: 10.1016/S0008-4182(06)80001-3. No abstract available.

    PubMed 16883356
  • Quigley HA. Glaucoma. Lancet. 2011 Apr 16;377(9774):1367-77. doi: 10.1016/S0140-6736(10)61423-7. Epub 2011 Mar 30.

    PubMed 21453963
  • Samples JR, Singh K, Lin SC, Francis BA, Hodapp E, Jampel HD, Smith SD. Laser trabeculoplasty for open-angle glaucoma: a report by the american academy of ophthalmology. Ophthalmology. 2011 Nov;118(11):2296-302. doi: 10.1016/j.ophtha.2011.04.037. Epub 2011 Aug 17.

    PubMed 21849211
  • Krasnov MM. [Laser puncture of the anterior chamber angle in glaucoma (a preliminary report)]. Vestn Oftalmol. 1972;3:27-31. No abstract available. Russian.

    PubMed 5078295
  • Van Buskirk EM, Pond V, Rosenquist RC, Acott TS. Argon laser trabeculoplasty. Studies of mechanism of action. Ophthalmology. 1984 Sep;91(9):1005-10. doi: 10.1016/s0161-6420(84)34197-5.

    PubMed 6493712
  • Alvarado JA, Alvarado RG, Yeh RF, Franse-Carman L, Marcellino GR, Brownstein MJ. A new insight into the cellular regulation of aqueous outflow: how trabecular meshwork endothelial cells drive a mechanism that regulates the permeability of Schlemm's canal endothelial cells. Br J Ophthalmol. 2005 Nov;89(11):1500-5. doi: 10.1136/bjo.2005.081307.

    PubMed 16234461
  • Bradley JM, Anderssohn AM, Colvis CM, Parshley DE, Zhu XH, Ruddat MS, Samples JR, Acott TS. Mediation of laser trabeculoplasty-induced matrix metalloproteinase expression by IL-1beta and TNFalpha. Invest Ophthalmol Vis Sci. 2000 Feb;41(2):422-30.

    PubMed 10670472
  • The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. The Glaucoma Laser Trial Research Group. Ophthalmology. 1990 Nov;97(11):1403-13.

    PubMed 2255512
  • Bylsma SS, Samples JR, Acott TS, Van Buskirk EM. Trabecular cell division after argon laser trabeculoplasty. Arch Ophthalmol. 1988 Apr;106(4):544-7. doi: 10.1001/archopht.1988.01060130590044.

    PubMed 3355425

Questions about this trial

What is this clinical trial studying?

An observational study of Glaucoma, Open-Angle and Glaucoma, Primary Open Angle, run by Fundación Oftalmológica Nacional at 1 site in Colombia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 17 Feb 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Colombia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Claudia Carvajal (+57-311-856-4991, crcarvajal@fon.org.co), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Intraocular pressure (time frame: Six months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02679482, which also lists 18 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Feb 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in